These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8708586)

  • 21. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
    Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
    Carlsen SM; Rossvoll O; Bjerve KS; Følling I
    J Intern Med; 1996 Mar; 239(3):227-33. PubMed ID: 8772621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial to evaluate the effectiveness of dietary advice by practice nurses in lowering diet-related coronary heart disease risk.
    Roderick P; Ruddock V; Hunt P; Miller G
    Br J Gen Pract; 1997 Jan; 47(414):7-12. PubMed ID: 9115804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators.
    Stewart RA; Sharples KJ; North FM; Menkes DB; Baker J; Simes J
    Arch Intern Med; 2000 Nov; 160(20):3144-52. PubMed ID: 11074745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
    Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
    J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Observed changes in the lipid profile and calculated coronary risk in patients given dietary advice in primary care.
    Price D; Ramachandran S; Knight T; Jones PW; Neary RH
    Br J Gen Pract; 2000 Sep; 50(458):712-5. PubMed ID: 11050787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
    Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
    Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects.
    Chan P; Tomlinson B; Lee CB; Pan WH; Lee YS
    Hypertension; 1996 Oct; 28(4):647-51. PubMed ID: 8843892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
    Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
    Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
    Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-density lipoprotein size, pravastatin treatment, and coronary events.
    Campos H; Moye LA; Glasser SP; Stampfer MJ; Sacks FM
    JAMA; 2001 Sep; 286(12):1468-74. PubMed ID: 11572739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
    Sasaki S; Nakagawa M; Nakata T; Azuma A; Sawada S; Takeda K; Asayama J;
    Circ J; 2002 Jan; 66(1):47-52. PubMed ID: 11999665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world"--randomized controlled trial.
    Vale MJ; Jelinek MV; Best JD; Santamaria JD
    J Clin Epidemiol; 2002 Mar; 55(3):245-52. PubMed ID: 11864795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
    Salonen R; Nyyssönen K; Porkkala E; Rummukainen J; Belder R; Park JS; Salonen JT
    Circulation; 1995 Oct; 92(7):1758-64. PubMed ID: 7671358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.